Adri Durant, MD
Urology · Indianapolis, INNPI 1285266056
Payments from drug & device makers
What this record shows
This record is dominated by grants: $10,000 of the $11,832 with a category attached, or 84.5%. Sumitomo Pharma America, Inc. accounts for 84.5% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $10,924 and has fallen 99.0% since, to $111 in 2025.
Across 26 payments — averaging $455.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$10K
- Coloplast$798
- Boston Scientific$307
- Axonics, Inc.$289
- Medtronic$164
- Progenics Pharmaceuticals, Inc.$125
- plus $149 from 4 others
What the payments were for
- Grants$10,00085%
- Food & beverage$1,83215%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 1 | $10,000 |
| Coloplast | 9 | $798 |
| Boston Scientific | 5 | $307 |
| Axonics, Inc. | 4 | $289 |
| Medtronic | 1 | $164 |
| Progenics Pharmaceuticals, Inc. | 1 | $125 |
| Cook Medical LLC | 2 | $52 |
| Fennec Pharmaceuticals, Inc. | 1 | $51 |
| Alnylam Pharmaceuticals Inc. | 1 | $26 |
| Intuitive Surgical | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,832 in reported general payments places this provider in the 80th percentile of 272 urology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 20 | $19,588 |
| Tamsulosin Hcl | 74 | $1,455 |
| Methenamine Hippurate | 18 | $1,011 |
| Trospium Chloride | 29 | $718 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 54 | $476 |
| Finasteride | 26 | $436 |
| Cefdinir | 40 | $289 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 39 | $221 |
| Chlorthalidone | 11 | $131 |
| Ciprofloxacin Hcl | 27 | $115 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 40 | $81 |
| Levofloxacin | 11 | $52 |
| Oxycodone Hcl | 44 | $31 |
Paid to pharmacies, not to this prescriber.
Other urology in Indianapolis
- Michael BorofskyIndianapolis$244K
- Marcelino RiveraIndianapolis$171K
- Helen BernieIndianapolis$100K
- Austen SladeIndianapolis$73K
- Jacob RustIndianapolis$57K
- Alvin WeeIndianapolis$46K
- Jason SprungerIndianapolis$30K
- Steven KheyfetsIndianapolis$18K
- Hristos KaimakliotisIndianapolis$12K
- Thairo PereiraIndianapolis$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.